Dosage Protocols
No FDA-approved dosing guidelines exist for MT-II. The following protocols are derived from clinical research and community reports:
Loading Phase:
- Initial dose: 0.1 mg (for tolerance assessment)
- Escalating to 0.25 mg daily for 2–4 weeks. The Phase I trial (Dorr et al.) tested doses up to 0.025 mg/kg, which corresponds to approximately 0.2 mg for an 80 kg individual
Maintenance Phase:
- 0.5–1 mg once or twice weekly after desired pigmentation is achieved
Important: This loading/maintenance protocol has no published clinical trial basis. The only clinical studies (Dorr 1996, Wessells 1998) used weight-based dosing in very small groups of 3 male volunteers. The protocol above is derived entirely from community use and has not been validated in controlled research.
UV Exposure: MT-II enhances the tanning response but does not eliminate the need for sun or sunbed exposure. Users typically combine the peptide with 10–20 minutes of UV exposure. MT-II does not provide complete UV protection and should not be used as a substitute for sunscreen.
Cycling: Some users implement 4–8 week breaks after 3–6 month periods to maintain receptor sensitivity, though clinical data supporting specific cycling protocols is limited.